Monthly blood transfusions decrease after four months of azacitidine.

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• Patients with MDS often require frequent red blood cell (RBC) transfusions, leading to significant morbidity and resource utilization.
• Azacitidine (AZA) is an established treatment for MDS associated with improved survival and transfusion independence.

Purpose of the Study:

• To quantify the reduction in RBC transfusion requirements in MDS patients treated with AZA.
• To determine the time course of RBC transfusion reduction following AZA initiation.
• To assess the durability of transfusion independence achieved with AZA therapy.

Main Methods:

• Retrospective audit of 51 MDS patients receiving AZA.
• Analysis of RBC transfusion burden 6 months prior to and up to 18 months after AZA initiation.
• Generalized linear mixed model used for data analysis.

Main Results:

• A significant reduction in monthly RBC units transfused was observed starting at 4 months (from 2.50 to 1.00 units/month).
• This 60% reduction was statistically significant (P = 0.002) and sustained beyond 12 months.
• While 56.7% achieved transfusion independence by 18 months, response durability varied, with some patients reverting to transfusion dependence.

Conclusions:

• AZA significantly decreases RBC transfusion burden and associated resource utilization in MDS patients.
• The findings highlight limitations in current WHO erythroid response criteria regarding response durability and fluctuations.
• AZA demonstrates a clinically meaningful impact on transfusion requirements in MDS.